tTau (Total Tau Commercial assay)
A soluble fragment of microtubule-associated tau protein, reflecting neuronal injury and enabling assessment of neurodegenerative processes.
Key features and values
- Quantifies total tau protein in cerebrospinal fluid (CSF) or plasma, indicative of neuronal damage.
- Reflects axonal degeneration, providing insights into neurodegenerative disease progression.
- Validated for use in human biofluids, ensuring reliable and reproducible measurements.
- Non-invasive tool for assessing neuronal injury, suitable for routine sampling.
- Elevated tTau levels correlate with increased neuronal damage in conditions such as Alzheimer’s disease.
- Useful for monitoring therapeutic response, with changes in tTau levels reflecting the efficacy of neuroprotective treatments.
- Facilitates research and development of targeted therapies by providing insights into tau-related neurodegeneration.
Description
The tTau biomarker assay is designed to quantify total tau protein levels in cerebrospinal fluid or plasma, serving as a specific indicator of neuronal injury. Tau is a microtubule-associated protein that stabilizes neuronal cytoskeleton; its release into biofluids reflects axonal damage. By measuring total tau, the assay provides a direct assessment of neurodegenerative processes.
This assay has been validated for use in human biofluids, demonstrating its reliability and reproducibility in various clinical and research settings. Elevated tTau levels have been associated with increased neuronal damage in conditions such as Alzheimer’s disease. The non-invasive nature of the test makes it suitable for routine monitoring of neuronal injury and the effectiveness of neuroprotective therapies.
In addition to its clinical applications, the tTau assay serves as a valuable tool in research, facilitating the study of tau-related neurodegeneration and the development of targeted treatments aimed at modulating neuronal injury processes.
